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Abstract 
NAD(P)H quinone oxidoreductase 1 (NQO1) is a multi-functional protein that catalyses the 
reduction of quinones (and other molecules), thus playing roles in xenobiotic detoxification 
and redox balance, and also has roles in stabilising apoptosis regulators such as p53.  The 
structure and enzymology of NQO1 is well-characterised, showing a substituted enzyme 
mechanism in which NAD(P)H binds first and reduces an FAD cofactor in the active site, 
assisted by a charge relay system involving Tyr-155 and His-161. Protein dynamics play 
important role in physio-pathological aspects of this protein. NQO1 is a good target to treat 
cancer due to its overexpression in cancer cells.  A polymorphic form of NQO1 (p.P187S) is 
associated with increased cancer risk and certain neurological disorders (such as multiple 
sclerosis and Alzheimer´s disease), possibly due to its roles in the antioxidant defence. 
p.P187S has greatly reduced FAD affinity and stability, due to destabilization of the flavin 
binding site and the C-terminal domain, which leading to reduced activity and enhanced 
degradation. Suppressor mutations partially restore the activity of p.P187S by local 
stabilization of these regions, and showing long-range allosteric communication within the 
protein. Consequently, the correction of NQO1 misfolding by pharmacological chaperones is 
a viable strategy, which may be useful to treat cancer and some neurological conditions, 
targeting structural spots linked to specific disease-mechanisms. Thus, NQO1 emerges as a 
good model to investigate loss of function mechanisms in genetic diseases as well as to 
improve strategies to discriminate between neutral and pathogenic variants in genome-wide 
sequencing studies. 
Keywords:  quinone oxidoreductase; multiple sclerosis; Alzheimer’s disease; protein 
misfolding; antioxidant enzyme; pharmacological chaperone 
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1. Introduction 
Water soluble quinone oxidoreductases are widely distributed in all Kingdoms of life [1].  At 
least two are known to occur in humans – NAD(P)H quinone oxidoreductase 1 (NQO1; EC 
1.6.5.2) and NRH quinone oxidoreductase 2 (NQO2; EC 1.10.5.1) [2].  The soluble, 
cytoplasmic quinone oxidoreductases are distinct from, and structurally different to, 
membrane bound enzymes which catalyse similar reactions.  The best characterised group 
of the transmembrane quinone oxidoreductases participate in oxidative phosphorylation 
and other electron transport processes.  These include mitochondrial complex I 
(NADH:quinone oxidoreductase; EC 7.1.1.2) and complex II (FADH2:quinone oxidoreductase 
or succinate-conenzyme Q reductase; EC 1.3.5.1) [3, 4].  In addition, there is a 
mitochondrial, membrane-bound sulphide quinone oxidoreductase (EC 1.8.5.8) which is 
involved in hydrogen sulphide metabolism [5].  NQO1 catalyses the two-electron reduction 
of quinones to hydroquinones.  This avoids the production of reactive semiquinone 
intermediates [6].  The precise in vivo role(s) of this reaction is/are unknown.  Furthermore, 
NQO1 is a relatively promiscuous enzyme and is capable of catalysing the reduction of a 
wide range of compounds, including quinones and their derivatives, aromatic nitrogen 
compounds, iron (III) salts and superoxide radicals [7-13].  Likely in vivo substrates include 
coenzyme Q10 (ubiquinone) and the oxidised form of vitamin K [14-16].  However, the 
enzyme’s role in the blood clotting cycle appears to be minor [17, 18]. Importantly, NQO1 is 
a stress-inducible protein by activation of the Nrf2 or Ah pathways, likely as a protective 
mechanism of the cell against stress [16, 19, 20].  The roles of NQO1 and the effects of its 
up- and down-regulation are summarised in Table 1. 
 
2. Structure and Enzymology of NQO1 
Human NQO1 is dimer of two identical 31 kDa subunits (Figure 1).  The two active sites are 
located at the interface between the subunits and are formed from residues from both 
polypeptide chains [21].  Each dimer has two FAD molecules bound, one in each active site.  
It was generally considered that these cofactors were “tightly bound”, although some early 
studies showed stoichiometries of less than 2 FAD:NQO1 dimer [22].  Recent work has 
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shown than FAD binding is slightly cooperative (h=0.84) meaning that, in effect while one 
cofactor molecule binds tightly, the second binds with lower affinity [23]. 
It is generally accepted that NQO1 has a substituted enzyme (or “ping-pong”) mechanism.  
NADH or NADPH can both function as the reducing agent and do so with almost equal 
catalytic efficiency [24].  In the first stage of the reaction, NAD(P)H reduces an FAD molecule 
in one NQO1’s two active sites.  NAD(P)+ then exits the active site, before the second 
substrate enters and is reduced by FADH2.  Thus, the two substrates never occupy the active 
site at the same time and never physically interact in the reaction cycle.  Redox titrations 
demonstrated that there is a two electron transfer, and no semiquinone intermediate.  The 
redox potential of the FAD/FADH2 pair was approximately -160 mV at 25 °C and pH 7 [25]. 
Evidence for the substituted enzyme mechanism comes from detailed, classical enzyme 
kinetic studies.  These demonstrated that NADPH alone could reduce the FAD cofactor in 
NQO1 (shown by disappearance of the characteristic yellow colour of the enzyme) [26].  The 
two half reactions both followed second order kinetics, with rate constants of 
approximately 109 M-1s-1 for the reduction of FAD by NAD(P)H and in the range 105 to 106 M-
1s-1 for reduction of quinone substrates by FADH2 [25]. 
Furthermore, Lineweaver-Burke plots of reciprocal rate against reciprocal concentration of 
NADPH at different concentrations of vitamin K3 or pyrroloquinoline quinone were parallel, 
a characteristic diagnostic feature of this mechanism [25, 26].  The deviation from this at 
higher substrate concentrations of vitamin K3 may be due to substrate inhibition (as has 
been observed in NQO2) [27]. 
The chemical mechanism of reduction by NQO1 has not been fully explored either 
experimentally or computationally.  However, the availability of crystal structures with a 
variety of ligands bound, enable some rational speculation (Figure 2).  It has been suggested 
that the first step in the reaction (reduction of FAD by NAD(P)H) occurs by direct hydride 
transfer between the two redox cofactors in the active site.  The most likely tautomer of the 
resulting FADH2 is the enolic form with the negative charge on O2F. This atom forms a 
hydrogen bond with the phenolic OH of Tyr-155, which can donate a proton to the FADH2.  
The resulting negative charge on Tyr-155 is neutralised by transfer of a proton from His-161.  
Thus, there is a net transfer of one positive charge from His-161 to NAD(P)+ [21]. In the 
second part of the reaction (reduction of the quinone), this process is reversed.  The proton 
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on O2F is transferred back to the OH of Tyr-155 and the imidazole ring of His-161 becomes 
fully protonated again. The result of this is the transfer of the proton from O2F, promoting 
the transfer of a hydride from N5F of FADH2 to the quinone. It is believed that the charge 
relay system formed by Tyr-155 and His-161 allows the reaction to take place without 
unfavourable charge separations [28]. Alteration of Tyr-155 to phenylalanine reduces 
activity to around 35% of wild-type [29, 30].  That this change does not abolish activity 
suggests that this residue is important in, but not critical to, catalysis and that other reaction 
pathways are possible.  Similarly, alteration of His-161 to glutamine does not abolish activity 
[30].  The charge relay system assists catalysis, but it may be that direct reduction of the 
FAD cofactor and quinone substrate can occur without it, albeit less efficiently.  
Alternatively, it may be that other residues can assist with charge separation.  It should be 
noted that there are two other tyrosine residues in the vicinity of the active site (Tyr-126 
and Tyr-128) and it is possible that they could have a minor role in catalysis. 
 
The best characterised inhibitor of NQO1 is the biscoumarin, dicoumarol (Figure 2).  This 
compound was discovered in the 1940s after cattle eating partially fermented clover died as 
a result of haemorrhages.  These were caused by the presence of dicoumarol in the feed 
which antagonised the blood clotting process [31, 32].  Dicoumarol is a competitive inhibitor 
which binds in the active sites of NQO1, directly blocking access by NAD(P)H [33].  Estimates 
for the inhibition constant (Ki) vary from 50 pM (from inhibition studies) to 120 nM (from 
isothermal titration) [26, 34].  Kinetically, it also has the key features of a competitive 
inhibitor, increasing the apparent Michaelis constant, with no effect on the maximum rate 
[22, 24].  Interestingly, dicoumarol causes a substantial decrease in the redox potential of 
the FAD/FADH2 pair to approximately -230 mV at 25 °C and pH 7.  This suggests that the 
inhibitor not only sterically hinders access t by NAD(P)H, but also affects the redox 
chemistry of the active site, potentially by altering its polarity [25, 35]. The widely used 
anticoagulant warfarin also inhibits NQO1 (Ki approximately 8 µM [36]), although vitamin K 
oxidoreductase is its pharmacologically important target (Figure 2) [18, 37].  Curcumin, a 
naturally occurring diarylheptanoid found in turmeric, also inhibits NQO1 (IC50 
approximately 5 µM), although it is not clear how important this property in the 
compound’s pharmacological roles (Figure 2) [38].  Early reports suggested that rat NQO1 
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exhibits negative cooperativity towards dicoumarol [22, 39].  Although this finding has not 
been verified in human NQO1, yeast Lot6p and human NQO2 demonstrate negative 
cooperativity towards the inhibitor resveratrol [40, 41].  The recent discovery of negative 
cooperativity of human NQO1 in FAD binding suggests a possible underlying cause given 
that these inhibitors bind by stacking over the isoalloxazine ring of FAD [23, 33]. 
 
3.  NQO1 in cancer 
The roles of NQO1 in cancer are well-established and well documented in the literature.  It 
has been observed that many cancer cells have increased levels of NQO1 [42].  Thus, the 
inhibition of NQO1 has been proposed as a possible therapy for a wide range of different 
types of cancer.  Experimentally, dicoumarol has been shown to kill pancreatic cancer cells 
in a mechanism linked to its inhibition of NQO1 and consequent rise in cellular levels of 
superoxide radicals [43, 44].  Dicoumarol is not an ideal anticancer agent since it has a 
number of other physiological effects, notably antagonism of the blood clotting cycle 
through inhibition of vitamin K oxidoreductase (VKOR, VKORC1, EC 1.1.4.1) and uncoupling 
of the mitochondrial proton gradient [32, 45-47].  Therefore, considerable efforts have been 
made to identify molecules which are effective NQO1 inhibitors, but lack these additional 
activities [48-57].  To date, no NQO1 inhibitors are used in anti-cancer therapy.  A number of 
potential anticancer agents are activated by reduction catalysed by NQO1, including EO9 
(apaziquone; 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(H-indole-4,7-indione)-propenol; 
Figure 3) [58, 59].  This compound is converted to a highly reactive form in vivo which then 
damages DNA and other biomolecules [59].  The compound initially showed considerable 
promise as an anticancer agent, but failed in clinical trials due to poor pharmacokinetics 
when administered intravenously [60].  More recent work has shown that EO9 may be 
effective if administered directly to the affected tissues [61]. 
Interestingly, a lack of NQO1 activity is linked to an increased risk of cancer.  A naturally 
occurring polymorphic form of the gene (C609T; NQO1*2; rs1800566) encodes a variant of 
the protein in which Pro-187 is substituted for serine (p.P187S; Figure 1).  This single amino 
acid change reduces the FAD affinity and stability of the protein, resulting in a substantial 
reduction in affinity (see Section 5.1, below).  This loss of activity has been linked to 
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increased lifetime probabilities of developing cancer in a number of tissues [62].  This 
polymorphism is common, with roughly one quarter of the human population having at 
least one C609T allele [63].  This is an unusually high rate for a deleterious polymorphism 
since these are typically selected against.  The reason for its high incidence is not known.  It 
can be speculated that the polymorphism confers some advantage in the heterozygous form 
(similar to the protection against malaria resulting from some mutations associated with 
sickle cell anaemia [64]).  Alternatively, since the effects of the polymorphism will most 
likely be seen in later life, they are unlikely to be prevent individuals with them from having 
children.  This would result in minimal selective pressure against the allele. 
The increased risk is particularly high when combined with other risk factors such as 
smoking or exposure to benzene [65-68]. Loss of NQO1 activity is most likely linked to 
cancer risk due to reduced antioxidant activity in the cell and the increased likelihood of one 
electron reduction of quinones to semiqunones which can attack DNA, proteins and lipids 
[69].  The loss of functional, folded NQO1 protein is likely to have a second effect.  NQO1 
binds to, and stabilises, the tumour suppressor proteins p53 and p73 [70-73].  Loss of these 
interactions may prevent apoptosis occurring in damaged and potentially cancerous cells 
[74]. 
 
4.  NQO1 in nervous system dysfunction 
The role, function and mechanism of NQO1 in nervous system dysfunction or diseases has 
not been as well studied as its role in cancer. As a key anti-oxidative enzyme, NQO1 is likely 
to play a role in the brain, given the potential for oxidative stress in this organ.  This results, 
in part, from the brain’s high oxygen consumption, along with the presence of high levels of 
polyunsaturated fatty acids, transition metals and low levels of antioxidant enzymes [75].  In 
adult rats, NQO1 is located in a subset of oligodendrocytes and in the Bergman glia in the 
cerebellum [76].  It has also been found in rodent mesencephalon astroglial cells, and in 
rodent dopaminergic neurons, as well as in healthy human substantia nigra neurons that are 
under extensive oxidative stress [77-79]. NQO1 knockout mice display behavioural 
symptoms, including seizures [76]. 
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Overexpression of NQO1 in human neuroblastoma cells (which are frequently used as a 
model of neurons) leads to increased resistance to cell death in response to 2-deoxyglucose, 
potassium cyanide, and lactacystin, but not hydrogen peroxide and serum withdrawal [80, 
81]. However, NQO1 depletion by RNAi increased vulnerability of these cells to the high 
hydrogen peroxide concentrations (>150 µM) [81].  Overexpression of NQO1 in these types 
of cells has additionally been found to enhance mitochondrial activity and resistance to the 
mitochondrial toxins rotenone and antimycin A [82]. Caffeinated and decaffeinated coffee, 
and chlorogenic acid induced NQO1 in a primary neuronal cell culture, and was found to be 
at least partly involved in the neuroprotection against hydrogen peroxide exposure, in 
contrast to some other published data [83]. Sulforaphane induced NQO1 in a mouse 
immature hippocampal neuronal cell line and was found to play a part in protection against 
oxygen-glucose deprivation-induced cell death [84].  NQO1 levels are also increased by 
isoflavone exposure in rat primary astrocytes, aminochrome-induced toxicity in a human 
astrocytoma cell line and β-Lapachone in rat primary astrocytes.  In each case, NQO1 
reduced the build-up of ROS and prevented cell death.  These effects could be reversed by 
dicoumarol or by knock-down of NQO1 [85, 86].  The anti-inflammatory effects β-Lapachone 
in microglia in response to LPS-stimulation may be mediated through induction of NQO1 
[87]. 
NQO1 maintains dopamine metabolites in their reduced state, enabling their subsequent 
detoxification by sulphation or glucuronidation (Figure 4) [88].  NQO1 may also play a 
catabolic role for serotonin. In rats, NQO1 inhibition by dicoumarol led to an increase in 5-
hydroxytryptamine (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA), and when administered 
in combination with a MAO inhibitor (L-deprenyl), led an increase in dopamine levels [89].  
Thus, a picture emerges in which NQO1 is one of a number of key enzymes in neuronal cells 
which are responsible for controlling oxidative stress and combatting the effects of some 
toxins.  Therefore, it seems reasonable to hypothesise that its levels may be increased in 
diseases which are associated with increased oxidative stress and that polymorphic forms 
which reduce its activity (e.g. p.P187S) may be associated with increased risks of these 
diseases. 
 
4.1 Parkinson’s Disease (PD) 
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Post-mortem tissue of humans with a diagnosis of PD have increased expression of NQO1 in 
astroglial and endothelial cells as well as dopaminergic neurons, especially in the substantia 
nigra pars compacta (SNpc) which is the area of the brain most implicated in the disease 
[90]. Genetic association studies with humans have revealed that the risk of PD was not 
significantly associated with the C609T NQO1 variant [91, 92].  Nevertheless, it appears that 
NQO1 plays a role in the neuroprotection of the dopaminergic system. Aminochrome only 
lead to neurotoxicity with the suppression of NQO1, manifesting itself with contralateral 
rotations and loss of dopaminergic neurons in rats [93]. Aminochrome toxicity was 
potentiated by NQO1 inhibition in a rat substantia nigra cell line.  Similarly, aminochrome-
induced disruption of actin and α- and β-tubulin was enhanced in the presence of 
dicoumarol [94, 95]. Dopaminergic cell lines with silenced expression of NQO1 show 
lysosomal dysfunction and increase in cell death in response to aminochrome [96, 97].  
Interestingly, D-dopa, the main treatment for PD, is known to induce oxidative stress, and 
administration of this drug to cultured rat astroglia upregulated NQO1 levels [98]. 
In the manganese(III) PD model in rats, neurotoxicity was potentiated by dicoumarol [99]. A 
decrease in NQO1 expression in the cerebral cortex and striatum has been observed in the 
rotenone model of PD, which was reversed through the administration of sulforaphane 
[100]. A novel compound (KMS04014, a dimeric derivative of ferulic acid) was found to 
induce NQO1 gene expression and protect dopaminergic neuronal cells in a dopaminergic 
neuronal cell line against oxidative stress generated by MPP+ (tetrahydrobiopterin, 1-
methyl-4-phenylpyridinium) and hydrogen peroxide [101]. In 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP, a prodrug for MPP+) treated mice (another animal model of PD), 
KMS04014 reduced the loss of tyrosine hydroxylase-immunopositive dopaminergic neurons 
in the substantia nigra and reduced the degeneration of the nigral neurons and striatal 
fibres [101].  Human neuroblastoma cell lines transfected with NQO1 were more resistant to 
dopamine toxicity [102]. A chemoprotectant (3H-1,2-dithiole-3-thione; D3T) was found to 
induce NQO1 and increase resistance to oxidative and electrophilic neurotoxicity in 
response to dopamine, 4-hydroxy-2-nonenal (HNE; an unsaturated aldehyde involved in the 
pathogenesis of PD) and hydrogen peroxide [103]. β-Phenethylamine, believed to play a role 
in PD, inhibited NQO1, presumably increasing neurotoxicity [104, 105]. 
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An overall picture emerges in which NQO1 plays a key role in mitigating some of the 
pathology of PD, particularly those mediated by oxidative stress.  It is, therefore, surprising 
that the C609T polymorphism is not associated with increased risk of PD.  Further studies in 
larger and/or more diverse population groups may be merited. 
 
4.2 Multiple Sclerosis (MS) 
Genetic association studies in a Greek population revealed higher frequency of the 
heterozygous and homozygous NQO1 C609T variant genotype in MS patients [106].  
However, a similar study in a Spanish population did not show an association [107].  A 
combination of polymorphisms in the GSTP (encoding Glutathione S-transferase P; EC 
2.5.1.18) and NQO1 genes has been observed with increased frequency in MS patients, and 
individuals with this combination were more likely to be non-responders to Natalizumab, a 
key treatment for MS [108, 109]. Post-mortem lesions from MS patients indicate 
upregulation of NQO1, especially in hypertrophic astrocytes and foamy macrophages, and 
to a smaller extent in oligodendroglial-like cells [110]. 
 
4.3 Alzheimer’s Disease (AD) 
It has been proposed that Aβ protein toxicity may be due to the formation of reactive 
oxygen species (ROS) [111]. Association between the C609T polymorphism in NQO1 and 
sporadic AD has been found [112, 113]. However, later studies did not observe a significant 
association; nonetheless, a homozygous wild-type genotype was found reduce the chances 
of sporadic AD [114, 115]. Hippocampal tissue samples from AD patients demonstrated 
increased NQO1 localised in neurofibrillary tangles (an end-stage manifestation of AD), the 
cytoplasm of hippocampal neurons, pyramidal neurons in areas of tau-presence, neurons in 
the frontal cortex, and astrocytes in the occipital lobe surrounding senile plaques.  This 
suggested that glial NQO1 upregulation is an early event and neuronal NQO1 is a later event 
[116, 117]. An increase in NQO1 was found in the hippocampus during the initial stages of 
the disease (2 months) in 3xTGAD mice which was then reduced by 6 months [118]. This 
suggests that in later stages antioxidant protection becomes insufficient to prevent 
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neuronal damage. Behaviourally, neophobia correlated with high expression of NQO1 in the 
initial stages of the disease [118].  Cyanidin-3-O-glucoside has been found to protect SH-
SY5Y cells against Aβ(1-40)-induced oxidative stress via increased expression of NQO1 [119]. 
The co-chaperone STUB1/CHIP, which has been found to target phosphorylated tau protein 
for degradation, was found to downregulate NQO1 at posttranslational level, and 
knockdown of STUB1/CHIP resulted in increased NQO1 expression in mice [120, 121]. 
Postmortem hippocampal tissue analysis has shown reduced NQO1 levels in AD patients 
which correlated with the presence of the C609T polymorphism [121]. In the animal model, 
3xTgAD mice, reduced levels and activity of NQO1 were observed in the hippocampus and 
cerebral cortex, areas associated with Aβ accumulation [122].  It is not clear if impaired 
NQO1 was reduced prior to neurodegenerative processes. Both the findings are in contrast 
to the previous studies which have reported increases in NQO1 [116, 117]. However, these 
studies looked at different stages in the pathological progression of AD. 
 
4.4 Schizophrenia 
A role for impaired antioxidant defence in schizophrenia has been proposed [123]. 
Adrenochrome, produced by the oxidation of adrenaline, has been found to be a neurotoxic 
substance, producing perception and thought disturbances [124]. NQO1 is known to be 
involved in the detoxification of adrenochrome [125]. However, no direct association has 
been found between the C609T NQO1 polymorphism and the development of schizophrenia 
[126].  However, the polymorphism was associated with susceptibility to tardive dyskinesia 
in patients with schizophrenia in some studies, but not others [126-128]. 
 
4.5 Mood Disorders 
Major Depressive Disorder (MDD) has been associated with a reduction in antioxidant 
defences and an increase in proinflammatory cytokines [129, 130]. NQO1 levels have been 
found to decrease in the cortex and hippocampus (regions involved in mood disorders) in 
the glucocorticoid mouse model for depression and anxiety [131]. These levels were found 
to increase following administration of fluoxetine (a selective serotonin reuptake inhibitor) 
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[131]. No association has been found between the C609T NQO1 polymorphism and mood 
disorders in a Korean population [132].  However, this does represent a relatively small 
sample of a single ethnic group.  Further studies over a range of ethnic groups may be 
useful. 
 
4.6 Atherosclerotic stroke 
Interestingly, the NQO1 C609T polymorphism was found to carry a reduced risk for ischemic 
stroke which may be due to these carriers having lower concentrations of blood coagulation 
factors [133, 134]. The effect is synergistic with non-smoking, low or zero alcohol 
consumption and polymorphisms in other the VKORC1 and GGCX (encoding γ-glutamyl 
carboxylase) genes [133]. 
 
5. Disease-associated NQO1 loss-of-function (LOF) due to protein destabilization misfolding 
 To carry out their biological activity, most proteins must fold into a defined three-
dimensional structure which lies in a free energy minimum of their conformational 
landscapes. Barriers that separate the native state from partially folded states are often 
small, and can be accessible through thermal fluctuations, with functional implications [135, 
136](Figure 5A). Thus, protein misfolding can be simply defined as any perturbation (i.e. an 
inherited missense mutation occurring in the germline) that impairs proper folding and 
function [136, 137]. Obviously, this concept has widely different meanings for different 
proteins according to features such as the soluble/membrane bound state, intracellular 
location and function. Importantly, missense mutations often compromise protein folding 
and lead to protein misfolding [138, 139]. In vivo, this scenario in which a protein decides 
whether to fold or misfold depends upon its interaction with the protein homeostasis 
network, a vast array of highly interactive proteins evolved to preserve proper quality of the 
proteome (i.e. protein homeostasis)[140, 141]. However, random mutations in natural 
proteins are universally associated to protein destabilization, particularly those buried in the 
structure [142]. Thus, missense mutations are often the cause of genetic diseases in which 
protein function is compromised (loss-of-function diseases) through changes in the stability 
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of the native vs. non-native states (Figure 5B). Whether a mutation leads to a given loss-of-
function molecular phenotype (aggregation, incorrect subcellular trafficking, enzyme 
inactivation, accelerated degradation) likely depends on the extent of mutational effects on 
protein stability, and how this propagates through the protein structure to promote the 
population of misfolding-associated partially folded states (Figure 5B; [143]). 
 Although the pathogenic manifestation of missense mutations may depend on many 
different factors [144, 145], it is likely that, generally, a certain degree of correlation exists 
between certain structural/energetic features of the mutation and the severity of disease 
phenotypes. These features may include magnitude of mutation-induced destabilization of 
the native state, the structural location of the mutated site and the propagation of stability 
effects to disease-associated protein states [143, 146-148]. The association of these features 
with pathogenicity is also particularly relevant to improve our capacity to predict the 
pathogenicity of mutations in genome-wide sequencing studies since it seems that a 
positive correlation exists between the pathogenicity of mutations found and their 
destabilizing effects [146]. Regarding NQO1, the Exome Aggregation Consortium (ExAC; 
http://exac.broadinstitute.org/) has compiled 73 missense variations in the NQO1 protein, 
with only three variants showing allele frequencies higher than 10-3, and the two most 
common, p.P187S/c.559C>T (frequency of 0.245) and p.R139W/c.415C>T (frequency of 
0.0382) have been characterized in detail (see below). In addition, 42 missense variants can 
be found in the COSMIC database (https://cancer.sanger.ac.uk/cosmic), of which only one, 
p.K240Q/c.718A>C, has been characterized experimentally.  In this section, we summarize 
our current knowledge on the consequences on NQO1 function, stability and misfolding of 
these three missense variants, while a more general discussion on the potential effects of 
cancer-related mutations (COSMIC) and variants of unknown pathogenicity found in human 
population (ExAC) are discussed in section 7.2. 
 
5.1. The p.P187S variant 
 The p.P187S variant is by the far the most extensively characterized missense variant 
in NQO1 (See Section 3, above). Early studies in cancer cell lines endogenously expressing 
this polymorphism revealed normal mRNA levels but virtually no NQO1 protein or activity, 
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suggesting folding and catalytic defects [149, 150]. The former effect was later determined 
to be caused by enhanced degradation of this polymorphism possibly due to ubiquitin-
dependent and independent pathways [151-153]. The low catalytic activity arises from a 10-
20-fold decrease in the binding affinity for FAD, thus easily explaining the isolation of this 
variant as an apo-protein [153, 154]. More recent biophysical and structural studies have 
revealed remarkable differences in the structure and dynamics between WT and p.P187S 
providing molecular insight into its low intracellular activity and stability [154-159]. 
 Strikingly, determination of the structure of full-length WT and p.P187S in a ternary 
complex with FAD (holo-protein) and C-terminal domain (CTD) binding inhibitors (PDB: 4CF6 
and 2F1O) showed virtually no difference at the protein structural level [155]. However, in 
the absence of inhibitors, p.P187S showed a highly dynamic (and possibly partially unfolded) 
CTD as supported by crystallographic, NMR spectroscopy and proteolysis studies (Figure 1; 
[155, 157]). The different stability and dynamics of the CTD in the p.P187S variant was 
shown to be critical for its enhanced ubiquitinylation and degradation of the protein even in 
the holo-state, while degradation of the WT enzyme seemed to simply operated through 
the levels of the apo-protein, and thus, the intracellular flavin levels [156, 157]. The 
thermodynamically unstable CTD in p.P187S might also act as initiation site for ubiquitin-
independent proteasomal degradation [160]. Importantly, these results pointed to the CTD 
as a target for pharmacological correction of the intracellular stability of p.P187S, further 
confirmed by using ligands binding to and stabilizing this domain [156, 157].  
 Understanding the defective FAD binding to p.P187S has even more been 
challenging. Thermodynamic analyses showed that p.P187S interferes with the binding 
cooperativity of WT NQO1 and FAD [23] making comparative structure-thermodynamic 
analyses very difficult. Further, the apo-state is very challenging to characterize using high-
resolution structural techniques and computational methods due to its intrinsic dynamics 
[158, 159], while characterization of their effects on the holo-state have revealed minimal 
changes [155]. Nevertheless, changes in structure and dynamics of the apo-state due to 
p.P187S have been demonstrated through molecular dynamics, mutational studies and 
thermodynamic analyses [157, 159, 161]. p.P187S seems to primarily affect the structure 
and dynamics of the binding site in the apo-state (particularly in the loop 57-66 and the 
region comprising Tyr127 and Tyr129; Figure 1), thus promoting the population of FAD 
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binding non-competent conformations in the apo-state ensemble and energetically 
penalizing binding [157, 159]. According to this view, an evolutionary-divergent mutation 
(p.H80R) and a phosphomimetic mutation at Ser82, were shown to increase and decrease 
the affinity of p.P187S for FAD acting on the population of binding competent states and the 
structure/dynamics of the loop 57-66 [159, 161, 162]. 
 p.P187S also affects the intracellular stability of p53 and p73 as interactors of 
NQO1 [152, 163, 164], although whether this reflects structural alterations, protein:protein 
interactions (PPI) or just mirrors the low intracellular stability of the polymorphism has been 
controversial. An active NQO1 enzyme, particularly with a reduced FAD cofactor, has been 
proposed to be critical for these PPI based on in vitro immunoprecipitation studies [152, 
163, 164]. However, biochemical and biophysical studies involving NQO1 species with 
virtually no activity (apo-P187S, C-terminal truncated NQO1, or NQO1 inhibited by 
dicoumarol or ES936) showed some capacity of these forms to interact with these 
oncosuppressors [158, 165]. Therefore, it seems that at least to some extent, destabilization 
of oncosuppressors by p.P187S reflects the low intracellular stability of this NQO1 variant 
[158].  
 It is remarkable that p.P187S affects functional sites of NQO1 located far away in the 
structure (at minimal distances of 9-17 Å) (Figure 1; [166]), including the FAD binding site, 
the dicoumarol binding site located in the CTD and the monomer:monomer interface 
(reducing the stability of the dimer) [154, 157, 158]. The fully buried location of Pro-187, 
and its non-conservative change to Ser, likely perturbs the protein packing and dynamics, 
and these effects propagate efficiently through the protein structure [143]. Interestingly, 
this propagation occurs in a non-trivial manner, as indicated by extensive mutagenesis 
studies [143, 158, 161]. Removal of the CTD essentially abolishes the effects of p.P187S on 
the remaining functional sites which show WT-like binding of FAD and thermal stability 
[158], consistent with the existence of allosteric communication between sites in NQO1 
which is perturbed by the polymorphism [158]. This allosteric network likely communicates 
differently stability and dynamic alterations originated at the Pro-187 site, as shown by the 
mild effects of the entropy-promoting P187G mutant in the FAD binding site and CTD 
stability as well as their larger effects on the stability of the monomer:monomer interface 
[166]. In addition, stabilizing mutations also likely communicate their effects through this 
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network in a complex manner, with the p.H80R variant locally stabilizing the FAD binding 
site and the monomer:monomer interface, while the p.E247Q variant locally stabilizes the 
CTD and this effect is also transmitted the FAD binding site located at 24 Å and synergizes 
with p.H80R, located 40 Å away. 
 
5.2. The p.R139W variant 
 A second, rarer, NQO1 polymorphism has also been associated with an increased risk 
of cancer.  The p.R139W/c.415C>T polymorphism (rs1131341; NQO1*3) was isolated from 
cancer cell lines resistant to treatment with MMC [167-169]. This nucleotide change causes 
primarily two effects: i) altered normal splicing of RNA leading to skipping exon 4 [167], and 
thus, rendering a very unstable protein lacking part of the FAD binding site [157, 167, 170]; 
ii) the amino acid exchange p.R139W, affects a residue located in a solvent exposed loop not 
close to the FAD binding site (Figure 1). This mutation in the full-length protein causes only 
mild effects on thermal stability, FAD binding or catalytic activity [154, 157, 167, 170]. The 
conformation and dynamics of the p.R139W variant has been shown to be slightly affected, 
which has led to the proposition that the main pathogenic consequence of this 
polymorphism is the perturbation of proper RNA splicing [154, 157, 170]. 
 
5.3. The p.K240Q variant 
 The p.K240Q/c.718A>C mutation has been found in one sample of renal cancer and 
predicted to be deleterious in the COSMIC database. The Lys-240 residue is solvent-exposed 
and located in the CTD as part of a highly stabilizing electrostatic network, and structural 
analyses have suggested that the effects of mutations at this site are expected to act locally 
on the CTD (Figure 1; [143, 166]). In addition, Lys-240 is not close to the FAD or dicoumarol 
binding sites or the monomer interface, and predicted to be only mildly destabilizing (about 
2 kcal·mol-1; [166]). Thus, not surprisingly, p.K240Q does not affect NQO1 thermal stability 
and only mildly decreases FAD binding affinity, while the most prominent effect is to 
increase the dynamics of the CTD [166]. Whether this affects the intracellular degradation of 
NQO1 is still unknown. Interestingly, introduction of more perturbing mutations, causing 
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charge-reversal (p.K240E) or altering protein packing and conformational entropy 
(p.K240G), induced greater destabilization of the CTD that propagated to the distant FAD 
binding site [166]. Thus, these analyses further supported the proposal of complex 
communication of mutational effects through the NQO1 structural ensemble in the context 
of an allosteric network. 
 
6. Potential for pharmacological intervention in misfolding of NQO1  
 Since protein destabilization is the core of protein misfolding, any approach to 
compensate mutation-induced destabilization should prevent it. Conceptually, we should 
search for ligands that selectively bind to the native state, thus decreasing the rate or extent 
of protein misfolding by the law of mass-action (i.e. increasing the height of the free energy 
barrier of misfolding in Figure 5B). This approach using native state ligands (called natural or 
pharmacological chaperones) has been developed for treating certain loss of function 
diseases over the last decades, either using natural compounds (e.g. vitamin/cofactor 
supplementation) or molecules identified upon high-throughput screening [171-178]. 
Another approach to correct misfolding includes proteostasis regulators which may boost 
globally or specifically certain nodes of the proteostasis network improving folding to the 
native state or preventing degradation of proteins [179, 180].  
  The pharmacological chaperone approach could be used to rescue the intracellular 
activity and stability of NQO1 polymorphisms and mutations. In the particular case of 
p.P187S, the most common and well-characterized NQO1 missense variant, the results 
gathered suggest that two different types of ligands would be necessary to boost its activity 
in vivo. First, riboflavin supplementation should increase the fraction of active holo-enzyme, 
although this treatment has mild positive effects on protein stability [157]. In principle, this 
treatment would cause negligible problems since it is efficiently used to treat many 
disorders associated with flavoproteins [181]. Finding the second type of ligand would be 
more challenging, since this would require binding to the CTD and increasing its stability 
[157]. Currently, the only well-characterized compound that increases the CTD stability in 
p.P187S and corrects its stability in cells is dicoumarol, a potent anti-coagulant and NQO1 
inhibitor [32]. Although inhibitors can be used to correct misfolding, as long as their 
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inhibitory effect is counterbalanced by intracellular concentrations of substrates [182], the 
high affinity and toxicity of dicoumarol do not favour its use as a pharmacological 
chaperone. However, as long as the CTD is identified as the target, high-throughput 
screening could be carried out for similar ligands to identify ligands with high stabilizing and 
low inhibitory effects. A potentially interesting ligand would mimic the effect of the E247Q 
variant that restores the stability of the CTD despite being located far from the 
NADH/substrate binding site [161]. A particular interesting screening would be among 
chemical libraries of FDA-approved molecules [183] in order to speed up their potential 
translation to the clinical realm. 
 The perturbations induced by p.P187S in the conformation of the NTD also alters 
proper interactions with Hsp40/Hsp70 chaperones [184] possibly contributing to protein 
misfolding and enhanced degradation. These alterations are likely caused by the increased 
population of the apo-state in p.P187S that increase the flexibility of the N-terminus [157]. 
Thus, p.P187S function and stability might  also be rescued by riboflavin supplementation 
(to form the holo-state) and with activators of the HSF-1/Nrf-2 pathways [179] to increase 
the availability of Hsp70 chaperones for proper folding and expression of the polymorphic 
variant [185]. In addition, proteasomal inhibition by the FDA-approved Bortezomib could 
also enhance p.P187S activity and stability [151, 153, 165] although proteasomal inhibition 
may have undesired non-specific effects in the stability of the proteome.  
 
7. NQO1 as a model for loss of function disease.  
 The multi-functional nature of NQO1, the diversity of disease-causing mechanisms 
and the pleiotropic effects of single amino exchanges presented so far, make NQO1 an 
excellent model to further understand loss of function diseases. Some of these aspects are 
discussed in this section. 
 
7.1. Structural and energetic determinants of proteasomal degradation in LOF diseases 
 It is often presumed, and only known in a few cases, that structural destabilization 
caused by missense mutations affect protein intracellular levels by acting on the 
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degradation rate of the variant proteins, and in this context, the ubiquitin-dependent 
proteasomal pathway plays a critical role [146, 147, 186]. Generally, regions with high 
flexibility and low local stability are associated with ubiquitin tagging and act as initiation 
sites for proteasomal degradation (so called degrons) [187, 188]. Therefore, how a missense 
mutation affects the degradation rate of a protein may depend on the direct activation of 
degrons or propagation of the destabilizing effect to them. Regarding the former factor, 
analyses have suggested at even mild mutational perturbations of the native state stability 
(in the range of 3 kcal·mol-1) can significantly increase the degradation rates of variant 
proteins [146, 147, 186]. To the best of our knowledge, the latter factor has not been 
explored in detail. We propose that detailed mutational studies in NQO1 can provide novel 
insight into the interplay between local structural and energetic destabilization and 
proteasomal degradation, with implications to understand disease-mechanisms and 
molecular evolution. The factors determining the proteasomal degradation of WT NQO1 
and the p.P187S variant are well established in structural terms and can be readily 
modulated by ligand binding [151, 154, 157]. Wild-type and p.P187S can be degraded in 
apo-state by either ubiquitin-dependent and independent proteasomal pathways, and the 
ubiquitin-dependent pathway seems to rely on the action of CHIP as ubiquitin E3 ligase 
[189, 190]. In principal, ubiquitylation of NQO1 does not require accessory proteins (such as 
molecular chaperones), although the interaction of NQO1 with Hsp70/Hsp40 may also play 
a role in the ubiquitin-dependent degradation of NQO1 [156, 191]. In addition, a variety of 
stabilizing and destabilizing mutations at different structural sites of NQO1 have been 
characterized in vitro [23, 143, 157-159, 161, 162, 166], which combined with studies of 
proteasomal degradation rates in cellular models and structural perturbation analyses can 
provide unprecedented insights into this interplay. NQO1 can also be used to gain insight 
into how evolutionary changes in local stability and due to post-translational modifications 
(PTMs) can translate into inter-species variations in proteasomal degradation rates as well 
as modulation of protein stability due to phosphorylation and other PTMs [161, 162, 192]. 
 
7.2. Prediction of the consequences of missense variations in the whole genome era 
 Advances in sequencing technologies are greatly increasing our knowledge of the 
protein sequence variability in the human proteome [193], and now, one of the main 
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challenges is to determine accurately and in a high-throughput manner the pathogenicity of 
missense variants [144, 146, 194-196]. Biophysical stability calculations and residue 
conservation analyses have emerged as potential tools to improve our prediction capacity of 
mutational effects on protein intracellular stability [146, 147, 186]. However, to improve 
this capacity we should consider an important aspect of mutational effects on proteins: the 
fluid-like properties of the protein interior that allow efficient propagation and dissipation 
of mutational effects to distant functional sites thus affecting multiple functional features 
(pleiotropy) [143, 197, 198]. Pleitropy could be a quite general (if not universal) 
phenomenon associated with missense mutations [143, 148, 166, 197, 199-213]. Recent 
structural and experimental perturbation analyses on NQO1 and other disease-associated 
proteins displaying the most common loss of function mechanisms have revealed that both 
the original stability perturbation at the mutated site and its propagation through the 
protein structure to promote different misfolding states to determine not only the severity 
of the phenotype, but also the phenotype itself [143].   
 Recent studies have systematically assessed the impact of disease-associated vs. 
neutral or common variants found in massive genome-sequencing initiatives [146, 147]. 
These studies have proposed that disease-causing variants may decrease protein 
intracellular stability due to a larger energetic perturbation of the native state stability, 
while variants found in the overall population typically show milder effects as they become 
more frequent.  To compare with these studies, we have compiled NQO1 variants found in 
cancer samples (COSMIC; N=41) and in overall population (ExAC; N=69) and carried out 
structure-based stability calculations by using the FoldX force-field [214]. Overall, the two 
sets of variants are quite similar, with a median destabilizing of typically 2-3 kcal·mol-1 
(Figure 6A). Although these values may appear mild, they are in the range shown to 
significantly decrease the intracellular stability of other disease-associated proteins [146, 
147], and in the particular case of NQO1, mutations affecting the cancer-associated Lys-240 
site destabilized it by 2-4 kcal·mol-1 and severely perturbed different functional features of 
the protein [143, 166]. The apparent bimodal distribution for the destabilizing effects 
(Figure 6A) likely reflects the larger destabilization caused by mutations affecting buried 
residues (Figure 6B), in agreement with previous large-scale and structure-based analyses 
[142] and also shown for a few disease-associated proteins [146, 147]. Importantly, the 
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effect of mutations affecting buried residues should percolate more efficiently through the 
structure and thus show stronger pleiotropic effects as recently found for p.P187S [143, 
198, 215, 216].  As found recently for other disease-associated proteins (such as 
phenylalanine hydroxylase or the human mismatch repair protein, MSH2)[138,139][217]), it 
appears that the neutrality of ExAC mutation in NQO1 positively correlates with their 
frequency in human population (Figure 6C). Clearly, p.P187S may represent an exception, 
and this could be related with different factors. For instance, in contrast to human 
monogenic disorders, cancer is a multi-factorial in which many different factors (i.e. genetic 
or environmental factor) may determine the molecular phenotype. In addition, NQO1 
expression is not required for normal development and physiology unless a heavy stress or 
burden is introduced [218], and counterintuitively, either NQO1 activity or inactivity may be 
associated with cancer development or progression due to its multiple roles in antioxidant 
defense, detoxification and interaction with tumour suppressor [185]. Still, we need further 
experimentation to understand how mutation-induced protein destabilization causes 
pleiotropic effects, and NQO1 seems to be an excellent model for that. 
 
7.3.  Loss of function diseases associated with human flavoproteins 
 Treatment of loss of function metabolic diseases with supplementation of cofactor 
precursors is a classic therapeutic approach [219]. NQO1 belongs to the set of human 
proteins constituting the flavoproteome, a set of a hundred proteins whose activity relies on  
FAD or FMN or related compounds [220]. A recent proteomic study has shown that most of 
human flavoproteins are very sensitive to starvation of the flavin cofactor, particularly 
NQO1 [156]. These effects seem to be mediated by specific recognition and degradation of 
apo-proteins by the ubiquitin-dependent proteasomal pathways [156]. Although it is 
appealing to apply this view to disease-associated mutation in human flavoproteins, we 
must also consider other factors. For instance, whether mutations alter the degradation 
pathway of the protein, as it has been shown for p.P187S which is efficiently degraded as 
the holo-protein [156, 157] or the cross-talk of ubiquitin-dependent degradation with other 
post-translational modifications [162]. Due to the rich diversity of post-translational 
modifications in NQO1 [192] and the availability of cancer-associated but uncharacterized 
NQO1 missense mutations, NQO1 emerges as an ideal case study to investigate further the 
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intracellular stability of human flavoproteins in health and disease. To end, recent work has 
also shown that changes in the chemical composition of the intracellular milieu, such as 
anion concentration and identity, could also affect flavin binding affinity and thus 
intracellular stability of human flavoproteins [221]. 
 
8.  Conclusions 
The extensive data which has now been gathered on NQO1 structure, dynamics, function 
and enzymology mean that there is a sound foundation upon which to build the search for 
lead molecules which act as pharmacological chaperones.  Any drugs developed from this 
work would have potential utility in restoring NQO1 activity in individuals who are 
homozygous for the C609T allele and thus at high risk of developing cancer.  They may also 
be useful in the treatment of cancers and some neurological conditions in people 
homozygous for the C609T allele.  This would be particularly the case for those diseases 
where increased risk (or increased risk of more severe symptoms) has been linked to this 
allele, i.e. multiple sclerosis and Alzheimer’s disease.  These molecules would also be useful 
chemical biology probes for further studies on the dynamics of NQO1.  Furthermore, the 
extensive knowledge base which has been established for NQO1 make it an excellent model 
for other loss of function diseases, particularly those involving flavoproteins.  It is likely that 
many of the principles which are being established for NQO1 will also apply to less well-
studied systems and diseases. 
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Figure legends 
Figure 1. Structure of human NQO1.  Structural location of the naturally-occurring and 
cancer-associated p.R139W, p.P187S and p.K240Q variants and those regions in NQO1 
associated with enhanced degradation (the CTD) and FAD binding. The figure was made 
using PDB:  2F1O [33].  
Figure 2.  Mechanism of NQO1.  The scheme shows the generally accepted catalytic 
mechanism for NQO1.  In the first stage NAD(P)H (only the reduced nicotinamide ring is 
shown here with the rest of the molecule represented here by R2) reduces FAD, resulting in 
a negative charge on the isoalloxazine ring.  This is then neutralised by transfer of a proton 
from Tyr-155, which is itself neutralised by His-161.  Reduction of the quinone substrate 
occurs by reversal of the electron movements in FADH2 and two protons are required from 
the solvent.  Only the isoalloxazine ring of FAD is shown with the rest of the cofactor 
represented by R1.  Similarly, only part of the side chains for Tyr-155 and His-161 are shown 
with the rest of the protein shown by R3 and R4.  NAD(P)H can be presumed to diffuse out of 
the active site once it has reduced the FAD.  It has been omitted from subsequent stages of 
the reaction scheme. 
Figure 3 A selection of compounds which interact with NQO1.  The structures of three 
NQO1 inhibitors (dicoumarol, warfarin and curcumin).  EO9, an anticancer agent which is 
activated by NQO1, is also shown. 
Figure 4 NQO1 maintains dopamine metabolites in the reduced state.  Dopamine can be 
oxidised to a quinone form which spontaneously rearranges to aminochrome.  NQO1 can 
catalyse the reduction of the aminochrome to its corresponding hydroquinone, which is 
required for detoxicifying it by sulphation or glucuronidation [88]. 
Figure 5. Protein energy landscape, misfolding and disease. (A) Structure-based free energy 
surface for the NQO1 monomer. The two folding intermediates I1 and I2 represent states in 
which the NTD is essentially folded while the CTD is largely (I2) or scarcely (I1) folded. 
Calculations were kindly performed and provided by Dr. Athi Naganathan (Indian Institute of 
Technology Madras, India) using a WMSE structure-based statistical mechanical model at 
298 K and using the structure PDB:  5EA2 [222] (see [197] for additional details); (B) 
Mutations can alter the kinetic and thermodynamic stability of the native state and 
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folding/unfolding intermediates leading to disease (i.e. degradation, aggregation, 
inactivation, etc)(adapted from [143]). 
Figure 6. Structure-based energetic calculations of the effects on NQO1 stability by 
mutations found in COSMIC and ExAC databases. (A) Mutational effects on stability for 
mutations in COSMIC (N=41) and ExAC (N=69). In the left panel, boxes show the median and 
25th/75th  percentiles, vertical lines show data within 1.5 times the interquartile range (IQR) 
and dots show outliers (>1.5·IQR). In the right panel, Violin plots showing the distribution of 
stability effects as well as the mean  s.d. for each data set (N=38 for COSMIC, N=63 for 
ExAC). Statistical analyses for these two populations provided a p value of 0.25. (B) 
Structural location and destabilization for COSMIC plus ExAC mutations showing no 
clustering for the magnitude of destabilizations as well as milder effects for surface 
mutations. Left and middle figures show the destabilizing effect mapped onto the structure 
(PDB 1D4A; [223]) following the colour code. The plot in the right shows average stability 
effects for COSMIC or ExAC mutations buried or exposed using a cut-off solvent exposure of 
10% based on GetArea (http://curie.utmb.edu/getarea.html) calculations. Statistical 
analyses provided a p value of 1.2·10-2 (COSMIC) and 4.4·10-4 (ExAC). (C) ExAC mutations 
cause milder protein destabilization as their frequency is increased in human population. 
The arrow indicates p.P187S as an outlier. Data are provided as changes in folding free 
energy vs. WT NQO1 (G). Calculations were carried out by FoldX [214] using the dimeric 
structure of NQO1 (PDB 1D4A; [223]). Statistical analyses were carried out using a two-tailed 
non-parametric Mann Whitney U test. 
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Table 1:  Major roles of NQO1 and effects of up/down regulation 
Catalytic roles 
Two electron reduction of quinones, avoiding semiquinone intermediates 
Reduction of reactive oxygen species 
Reduction of dopamine metabolites to maintain them in the correct form for 
detoxicifcation 
Minor role in vitamin K cycling 
Activation of potential anticancer agents, e.g. EO9 
Roles depending on protein-protein interactions 
Stabilisation of p53 and p73 
Interactions with 20S proteasomal components control proteasomal activity 
Effects of up-regulation 
Increased survivability of cancer cells 
Response to cellular stress; assists in reducing free radical load 
Increased resistance of cells to some reagents which cause free radical stress 
Effects of down-regulation or inhibition 
Increased potential for semiquinone build-up and free radical damage; consequent 
increased cancer risk 
Reduced viability of cancer cells 
Abnormal behaviour and seizures in rats 
Neuronal cells more sensitive to aminochrome toxicity 
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